NEUARTIGE THIOPHOSPHORAMIDITE

European patent · EP3728590 · In force

Register entry

Publication number
EP3728590
Application number
EP18830479
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 21, 2018
Published
Oct 28, 2020
Granted
Jul 2, 2025
Protection ends at the latest
Dec 20, 2038
Next annual fee due
Dec 31, 2026
IPC classes
C12N 15/11 (2006.01)
C07F 9/165 (2006.01)
C07H 19/10 (2006.01)
C07H 19/20 (2006.01)
C07H 21/00 (2006.01)
Priority
WO PCT/CN2017/118043 22.12.2017
EP 18198487 03.10.2018
PCT application
PCT/EP2018/086457 21.12.2018
PCT publication
WO2019/122277 27.06.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 18, 2026

    Change

    Published in Swissreg on 18.05.2026

  2. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  3. Jul 2, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 02.07.2025

Parties

Holder

Roche Innovation Center Copenhagen A/S

Fremtidsvej 3, 2970 Hørsholm, DK

Inventor

BLEICHER, Konrad

4070 Basel

DUSCHMALÉ, Joerg

4070 Basel

DUSCHMALÉ, Martina Brigitte

4126 Bettingen

HANSEN, Henrik Frydenlund

2970 Hørsholm, DK

KOCH, Troels

2970 Hørsholm, DK

LI, Meiling

4070 Basel

SCHAEUBLIN, Adrian

4070 Basel

SHU, Xi

Hubei, 430075, CN

WU, Yong

Hubei, 430075, CN

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.